




(86) **Date de dépôt PCT/PCT Filing Date:** 2010/07/21
(87) **Date publication PCT/PCT Publication Date:** 2011/01/27
(45) **Date de délivrance/Issue Date:** 2016/10/04
(85) **Entrée phase nationale/National Entry:** 2012/01/19
(86) **N° demande PCT/PCT Application No.:** US 2010/042788
(87) **N° publication PCT/PCT Publication No.:** 2011/011541
(30) **Priorité/Priority:** 2009/07/21 (US61/227,124)

(51) **Cl.Int./Int.Cl. A61K 9/20** (2006.01),
A61K 31/295 (2006.01)
(72) **Inventeur/Inventor:**
LE, HENRY TRONG, US
(73) **Propriétaire/Owner:**
KERYX BIOPHARMACEUTICALS, INC., US
(74) **Agent:** GOWLING WLG (CANADA) LLP

(54) **Titre : FORMES POSOLOGIQUES DE CITRATE FERRIQUE**
(54) **Title: FERRIC CITRATE DOSAGE FORMS**



(57) **Abrégé/Abstract:**
The disclosure relates to ferric citrate tablets and dosage forms.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
27 January 2011 (27.01.2011)(10) International Publication Number
WO 2011/011541 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) *A61K 31/295* (2006.01)

(21) International Application Number:

PCT/US2010/042788

(22) International Filing Date:

21 July 2010 (21.07.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/227,124 21 July 2009 (21.07.2009) US

(72) Inventor; and

(71) Applicant : **LE, Henry Trong** [US/US]; 38 Priscilla Lane, Englewood Cliffs, New Jersey 07632 (US).(74) Agents: **WALKER, David** et al.; 370 Seventeenth Street, Suite 4700, Denver, Colorado 80202 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: FERRIC CITRATE DOSAGE FORMS

(57) Abstract: The disclosure relates to ferric citrate tablets and dosage forms.




FIG.1

WO 2011/011541 A1



— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))* — *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*

FERRIC CITRATE DOSAGE FORMS

5

FIELD

The field of the disclosure generally relates to pharmaceutical compositions of ferric citrate, methods for their use in treating medical conditions, and processes for their manufacture.

10

BACKGROUND

US 5,753,706 discloses that ferric citrate compounds can be used to control phosphate metabolism and prevent metabolic acidosis in patients.

Ferric citrate compounds can be used with patients suffering from renal failure associated with hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition. Ferric citrate also is used as a food supplement and additive. Ferric citrate is characterized as a light brown to beige powder, odorless and slightly ferruginous tasting. According to the Merck Index, ferric citrate is slowly but completely soluble in cold water and readily soluble in hot water but diminishes in solubility with age.

US 6,903,235 discloses that ferric citrate is commercially available in the form of a combination of iron and citric acid of indefinite composition.

The '235 Patent explains that the indefinite composition is likely due to difficulties encountered in its preparation but that those knowledgeable in the art understand and necessarily accept that commercially available ferric citrate contains different molar ratios of iron and citric acid and also contains different amounts of hydrate.

WO 2004/074444 discloses processes for making ferric organic compounds, such as ferric citrate, with enhanced dissolution rates. WO 2007/022435 is a continuation-in-part of WO 2004/074444 and discloses processes for making ferric organic compounds soluble over a wide pH range and having a large surface area. WO 2007089577 is directed to methods of treating soft tissue calcification using ferric organic compounds, such as a ferric citrate compound. WO 2007089571 is directed to methods of treating chronic kidney disease using ferric organic compounds, such as ferric citrate compounds.

SUMMARY

In one aspect, the disclosure is directed to a tablet including ferric citrate. In some embodiments, the tablet can include at least 65 weight percent ferric citrate.

In another aspect, the disclosure is directed to a tablet comprising granule particles.

5 The granule particles include ferric citrate and a binder, and the mean surface area to mass ratio of the granule particles is equal to or greater than 1 m^2 per gram. In various embodiments, the mean surface area to mass ratio of said granule particles is equal to or greater than 5 m^2 per gram or 10 m^2 per gram.

10 In another aspect, the tablet can include at least 70 weight percent ferric citrate, at least 80 weight percent ferric citrate, or at least 90 weight percent ferric citrate.

In another aspect, the binder can be one or more of hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), sodium alginate, alginic acid, guar gum, acacia gum, xanthan gum, carbolpol, cellulose gum (carboxymethyl cellulose), ethyl cellulose, maltodextrin, PVP/VA, povidone, microcrystalline cellulose, starch (partially or fully
15 pregelatinized starch) and methyl cellulose.

In another aspect, the tablet can include various additional components including, for example, one or more disintegrants and/or one or more lubricants. The disintegrant can be one or more of microcrystalline cellulose, croscarmellose sodium, crospovidone, sodium starch glycolate, and starch. The lubricant can be one or more of magnesium stearate,
20 calcium stearate, sodium stearyl fumarate, polyethylene glycol (molecular weight above 3350), sodium lauryl sulfate, talc, mineral oil, leucine, and poloxamer. In some embodiments, the tablet can include between approximately 65% and 92% ferric citrate, between approximately 4.5% and 30% binder, and between 0.5% and 3% lubricant. The binder can have disintegrant properties. The binder can be pregelatinized starch.

25 In another aspect, the tablet can be between approximately 65% and 92% ferric citrate, between approximately 4.5% and 30% binder, between approximately 1.5% and 15% disintegrant, and between 0.5% and 3% lubricant.

Various additional components in the tablet can include microcrystalline cellulose, pregelatinized starch and sodium stearyl fumarate. In one embodiment, the ferric citrate can
30 be present at approximately 85 weight percent, the microcrystalline cellulose present at approximately 4 weight percent, the pregelatinized starch present at approximately 9 weight percent, and the sodium stearyl fumarate present at approximately 2 weight percent.

In another aspect, the tablet can have between approximately 10% and 60% of ferric citrate dissolved in about 15 minutes, between approximately 30% and 90% of ferric citrate

dissolved in about 30 minutes and at least approximately 60% of the ferric citrate dissolved in about 60 minutes in a dissolution test according to test method USP <711>. The tablet can have a dissolution of at least 90% within 30 minutes in a dissolution test according to test method USP <711>. The tablet can show a dissolution of at least 90% within 60 minutes in a dissolution test according to test method USP <711>.

The tablet can show a disintegration time of less than 30 minutes in a disintegration test according to test method USP <701>. The tablet can show a disintegration time of greater than 30 minutes in a disintegration test according to test method USP <701>.

The tablet can include approximately 1000 mg of ferric citrate, approximately 667 mg of ferric citrate, approximately 500 mg of ferric citrate, approximately 250 mg of ferric citrate, or approximately 125 mg of ferric citrate.

In various aspects, the LOD (loss on dried) % water in the tablet is less than 20% water w/w. In other aspects, the LOD % water of the tablet is less than 15% water w/w. In still other aspects, the LOD % water of the tablet is less than 10% water w/w.

In various aspects, at least 80% of the ferric citrate in the tablet is dissolved in a time less than or equal to 60 minutes as measured by test method USP <711>.

In another aspect, the tablet includes a disintegrant. In certain embodiments, the disintegrant can be selected from one or more of microcrystalline cellulose, croscarmellose sodium, crospovidone, sodium starch glycolate, and starch.

In another aspect, the tablet includes a lubricant. In certain embodiments, the lubricant can be selected from one or more of magnesium stearate, calcium stearate, and sodium stearyl fumarate.

In another aspect, the disclosure is directed to a method of preparing a ferric citrate tablet. The method includes mixing the ferric citrate with one or more binders under conditions in which the LOD % water does not exceed 25% to form ferric citrate granules. Granulation can be performed by any method known in the art (e.g. fluid bed granulation or high shear granulation). The ferric citrate granules are then tableted.

In another aspect, the tablets are heated to above 50°C after tableting.

The tablets can be used for the prophylaxis or treatment of a variety of diseases or disease states, including, but not limited to, hyperphosphatemia.

Embodiments of the method can include one or more of the features described above or herein.

The details of various embodiments are set forth in the accompanying drawings and the description below. Features and advantages of various embodiments are apparent from the description, the drawings, and the claims.

DESCRIPTION OF THE DRAWINGS

Those skilled in the art will understand that the drawings, described herein, are for illustration purposes only. The drawings are not intended to limit the scope of the present disclosure.

Fig. 1 is a chart showing hardness as a function of compression force for Formulations 1-5.

Fig. 2 is a chart showing friability as a function of compression force for Formulations 1-5.

Fig. 3 is a chart showing disintegration time as a function of compression force for Formulations 1-5.

Fig. 4 is a chart showing dissolution time for Formulations 1 and 3-5.

Fig. 5 is a chart showing hardness as a function of compression force for Formulations 6-8 and 11.

Fig. 6 is a chart showing friability as a function of compression force for Formulations 6-8 and 11.

Fig. 7 is a chart showing disintegration time as a function of compression force for Formulations 6-8 and 11.

Fig. 8 is a chart showing dissolution time for Formulations 6-8 and 11.

Fig. 9 shows the dissolution time different tablets that were pre-dried and post-dried.

DETAILED DESCRIPTION

Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).

Tablets

In one aspect, the formulation is a tablet that includes ferric citrate and a binder. As is used herein, a "tablet" is a material produced by compression force, such as with a tableting machine. In other embodiments the formulation or tablet can include ferric citrate, a binder, a lubricant and a disintegrant. The tablet or formulation can be used as a prophylaxis or

treatment for hyperphosphatemia by administering the tablet or formulation in an effective amount or amounts known in the art.

The formulation can be characterized as highly drug loaded with the ferric citrate present in the formulation at values of greater than approximately 65 % by weight of the formulation, greater than approximately 70% by weight of the formulation and as high as approximately 92% of the formulation. Intermediate values such as approximately 80% by weight ferric citrate, approximately 85% by weight ferric citrate and approximately 90% by weight ferric citrate also can be used in the ferric citrate formulation. The characteristics of the tablet produced at these highly loaded weight percentages are controlled by variables such as binder, binder amount, disintegrant, disintegrant amount, formulation method used (e.g., granulation, direct compression), tableting parameters, etc. Thus if a tablet is made and it has a slight amount of lamination or capping, by varying one or more of the above variables, the lamination or capping can be corrected.

In various embodiments, the tablet formulation contains one or more components selected from among one or more binders, one or more lubricants, and one or more disintegrants.

The binder can be any binder known in the art. Without limitation, examples of the binder can include one or more of hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), sodium alginate, alginic acid, guar gum, acacia gum, xanthan gum, carbolpol, cellulose gum (carboxy methyl cellulose), ethyl cellulose, maltodextrin, PVP/VA, povidone, microcrystalline cellulose, starch (partially or fully pregelatinized starch) and methyl cellulose. The maltodextrin, PVP/VA, and methyl cellulose function as immediate release binders when used in the ferric citrate formulations.

It also should be understood that combinations of binders can be used to control and vary the effect of the binder. For example, a binder system can be made up of hydroxypropyl cellulose and polyvinyl pyrrolidone (povidone) with or without microcrystalline cellulose. One or both of the hydroxypropyl cellulose and povidone can be replaced with pregelatinized starch.

In various aspects, the tablet can include a lubricant. As an example of a lubricant for the ferric citrate formulations, magnesium stearate, calcium stearate, sodium stearyl fumarate and combinations can be used. Other suitable lubricants include one or more of polyethylene glycol (molecular weight above 3350), sodium lauryl sulfate, talc, mineral oil, leucine, and poloxamer.

In various aspects, the tablet can include a disintegrant. The disintegrant can be included in the formulation. The disintegrant can be the same as or different from the binder. By way of example and not limitation, microcrystalline cellulose has both binder and disintegrant properties and microcrystalline cellulose can be use as the sole
5 binder/disintegrant in the formulation. Examples of other suitable disintegrants include croscarmellose sodium, crospovidone, sodium starch glycolate, and starch.

The binder can be present in the formulation in an amount ranging from approximately 4.5% by weight to approximately 30% by weight. The disintegrant can be present in the formulation in an amount ranging from approximately 1.5% by weight to
10 approximately 15% by weight. In various embodiments, some non-starch disintegrants are often used at lower ranges, e.g., as low as 0.25% and thus the disintegrant present in the formulation can be as low as 0.25% in some conditions.

The lubricant can be present in the formulation in an amount ranging from approximately 0.5% by weight to approximately 3% by weight. It should be understood that
15 some components, such as microcrystalline cellulose, can function with both disintegrant and binder properties.

The weight of individual tablets can depend upon the final dosage to be produced; e.g. 125mg, 250mg, 500mg, 667mg, 750mg and 1,000mg of Ferric citrate.

In various embodiments, tablets are coated to a weight gain of approximately 2% to
20 5% using an Opadry™ suspension or equivalent in a perforated pan coater. As noted above, calcium stearate and Opadry purple can be replaced with or used with a different lubricant or coating system, respectively.

Tablets Having High Surface Area Per Unit Mass

In one variation, the disclosed tablets contain granule particle size having a
25 significantly higher mean surface area per unit mass than previous ferric citrate formulations. It has been discovered that the increased surface area per unit volume results in immediate release dissolution times (greater than 80% at 60 minutes after administration as determined by United States Pharmacopeia (USP) test <711, described in United States Pharmacopeia Compendium of Standards, USP 30 NF 25, Vol. 1 p. 276-284 (2007)).

30 Without wishing to be limited to a specific theory or mode of action, the increased granular surface area of granules in the tablet results in an increased amount of ferric citrate exposed to the solvent. The immediate release dissolution times are significantly reduced in a reduced tablet size.

In additional variations, the tablets disclosed herein can be designed to have a mean granule particle surface area to mass ratio equal to or greater than 1 square meter per gram. In further variations, the tablet has a mean granule particle surface area to mass ratio equal to or greater than 2 square meters per gram. In further variations, the formulation has a mean granule particle surface area to mass ratio equal to or greater than 4 square meters per gram. In further variations, the formulation has a mean granule particle surface area to mass ratio equal to or greater than 6 square meters per gram. In further variations, the formulation has a mean granule particle surface area to mass ratio equal to or greater than 8 square meters per gram. In further variations, the formulation has a mean granule particle surface area to mass ratio equal to or greater than 10 square meters per gram. In further variations, the formulation has a mean granule particle surface area to mass ratio equal to or greater than 15 square meters per gram. In further variations, the formulation has a mean granule particle surface area to mass ratio equal to or greater than 20 square meters per gram. In further variations, the formulation has a mean granule particle surface area to mass ratio equal to or greater than 30 square meters per gram. In further variations, the formulation has a mean granule particle surface area to mass ratio equal to or greater than 40 square meters per gram. In further variations, the formulation has a mean granule particle surface area to mass ratio equal to or greater than 50 square meters per gram. The increased surface area per particle in a tablet resulted in a significantly increased dissolution rate.

In other variations, the tablets have reduced water content. In one embodiment, the granular water content as measured by LOD % is less than 20%. In another embodiment, the granular water content as measured by LOD % is less than 19%. In another embodiment, the granular water content as measured by LOD % is less than 18%. In another embodiment, the granular water content as measured by LOD % is less than 17%. In another embodiment, the granular water content as measured by LOD % is less than 16%. In another embodiment, the granular water content as measured by LOD % is less than 15%. In another embodiment, the granular water content as measured by LOD % is less than 14%. In another embodiment, the granular water content as measured by LOD % is less than 13%. In another embodiment, the granular water content as measured by LOD % is less than 12%. In another embodiment, the granular water content as measured by LOD % is less than 11%. In another embodiment, the granular water content as measured by LOD % is less than 10%. In another embodiment, the granular water content as measured by LOD % is less than 9%. In another embodiment, the granular water content as measured by LOD % is less than 8%. In another embodiment, the granular water content as measured by LOD % is less than 7%. In another embodiment, the

granular water content as measured by LOD % is less than 6%. In another embodiment, the granular water content as measured by LOD % is less than 5%.

As will be understood to those of skill in the art, in various embodiments LOD is a method of thermogravimetric moisture determination: In thermogravimetric processes the moisture of a material includes substances that volatilize during warming, and therefore contribute to the material's loss of mass. Alongside water this may also include alcohol or decomposition products. When using thermogravimetric measurement methods (drying using infrared, halogen, microwaves or ovens) no distinction is made between water and other volatile components.

10 *Friability*

Friability generally measures the mechanical strength of tablets. During the process of coating, transportation, packing, and other processes, tablets can lose some weight. To measure the weight loss the samples are counted and weighed.

In various embodiments, friability test is performed as described in United States Pharmacopeia Compendium of Standards (2007).

Method of Making Tablets

In one tableting method, the tablets can be prepared in three steps. First, granules of ferric citrate and binder are formed. Second, a lubricant is added to the formulation before tableting. Third, the tablet is dried after an optional coating step.

Granulation

Ferric Citrate, such as pharmaceutical grade ferric citrate described, for example, in US patent# 6,903,235 B2, can be granulated by any method known in the art. Exemplary methods of granulation include fluid bed granulation, high shear granulation and direct compression granulation.

In embodiments in which the moisture of the formulation was brought to the level above 25% LOD at any point resulted in a substantially lower surface area per gram of particle. This can be accomplished, for example, by limiting the quantity of water introduced, or by air blowing and monitoring the amount of water in a formulation.

To increase the surface area to mass ratio of ferric citrate particles to greater than 1 square meter per gram, or in other embodiments greater than 10 square meter per gram, the moisture content of the granules is maintained at below 25% LOD throughout formation of granules. In certain variations, the moisture content of the granules is maintained at below

24% LOD, 23% LOD, 22% LOD, 21% LOD, or 20% LOD, throughout formation of granules.

Without wishing to be held to a particular mechanism or mode of action, it is hypothesized that keeping the amount of water below 25% LOD during granulation maintains granules with a high surface area per mass ratio. The addition of water in higher amounts at any time during the granulation process results in formation of larger granules with a lower mean surface area to mass ratio. The lower surface area to mass reduces the dissolution rate below the rate for an immediate release formulation. The measured lower mean surface area to mass ratio of granules results in slower dissolution, and release characteristics.

In various embodiments, it has been observed that the reduced surface area to weight ratio of the ferric citrate formulation is irreversible after addition of moisture at above 25% LOD. Accordingly, the percent water is kept below 25% during granulation in various embodiments.

Blending

In various embodiments, one or more lubricants can be blended with the granules. In various embodiments, a non-limiting list of lubricants includes stearates such as calcium stearate and magnesium stearate, sodium stearyl fumarate, stearic acid, talc, polyethylene glycol, hydrogenated vegetable oils, aluminum stearate, sodium benzoate, sodium acetate, sodium chloride, leucine, Carbowax™, and Magnesium Lauryl Sulfate. Certain starches, such as starch 1500, can also be considered lubricants, as they have some lubricant properties when used in direct compression application. Any lubricant known in the art can be used, including any of those disclosed in the Handbook of Pharmaceutical Excipients fifth edition.

Multiple lubricants can be combined.

In certain embodiments, a greater quantity of lubricant than is ordinarily used in the art can be used. It has been discovered that surprisingly, the quantity of lubricant must be higher than recommended or understood in the industry to reduce the quantity of sticking in the ferric citrate tablets.

In certain variations, a combination of magnesium or calcium stearate and sodium stearyl fumarate is used as a lubricant. In further embodiments, the lubricant is a combination of calcium stearate and sodium stearyl fumarate. In various embodiments, a greater quantity of calcium stearate than is recommended in the art can be used. As described in the Handbook of Pharmaceutical Excipients fifth edition, the recommended quantity of calcium stearate is a maximum of 1.0% w/w. In one embodiment, the quantity of calcium stearate is equal to or greater than 2.0% w/w. In another embodiment, the quantity of

calcium stearate is equal to or greater than 2.2% w/w. In another embodiment, the quantity of calcium stearate is equal to or greater than 2.4% w/w.

Likewise, in various embodiments, a greater quantity of sodium stearyl fumarate than the recommended 0.5 – 2.0% w/w concentration can be used. In one embodiment, the quantity of sodium stearyl fumarate is greater than or equal to 2.1% w/w. In another embodiment, the quantity of sodium stearyl fumarate is greater than or equal to 2.2% w/w. In another embodiment, the quantity of sodium stearyl fumarate is greater than or equal to 2.3% w/w. In another embodiment, the quantity of sodium stearyl fumarate is greater than or equal to 2.4% w/w. In another embodiment, the quantity of sodium stearyl fumarate is greater than or equal to 2.5% w/w. In another embodiment, the quantity of sodium stearyl fumarate is greater than or equal to 2.6% w/w. In another embodiment, the quantity of sodium stearyl fumarate is greater than or equal to 2.7% w/w.

Post-Tableting Drying

A drying step can be performed after tableting. In the absence of drying the tablet after tableting, it was discovered that the dissolution rate of tablets increased over time. Drying maintained the immediate release characteristics of the ferric citrate tablets as disclosed herein. Without being limited to a specific mechanism or mode of action, it is believed that granule size increases due to the presence of residual water, and the drying step maintains the large surface area per unit weight of the original granules.

In one embodiment, the final granular water content as measured by LOD % is less than 20%. In another embodiment, the final granular water content as measured by LOD % is less than 19%. In another embodiment, the final granular water content as measured by LOD % is less than 18%. In another embodiment, the final granular water content as measured by LOD % is less than 17%. In another embodiment, the final granular water content as measured by LOD % is less than 16%. In another embodiment, the final granular water content as measured by LOD % is less than 15%. In another embodiment, the final granular water content as measured by LOD % is less than 14%. In another embodiment, the final granular water content as measured by LOD % is less than 13%. In another embodiment, the final granular water content as measured by LOD % is less than 12%. In another embodiment, the final granular water content as measured by LOD % is less than 11%. In another embodiment, the final granular water content as measured by LOD % is less than 10%. In another embodiment, the final granular water content as measured by LOD % is less than 9%. In another embodiment, the final granular water content as measured by LOD % is less than 8%. In another embodiment, the final granular water content as

measured by LOD % is less than 7%. In another embodiment, the final granular water content as measured by LOD % is less than 6%. In another embodiment, the final granular water content as measured by LOD % is less than 5%.

Examples

5 The following examples describe the preparation and properties of various dosage forms and methods described herein. It will be apparent to those skilled in the art that many modifications, both to materials and methods, can be practiced without departing from the scope of the disclosure.

Example 1

10 The following exemplary formulations and formulation techniques for ferric citrate provide data showing characteristics for the formulations or tablets, including data such as dissolution, disintegration, and friability.

 The sources for some of the materials included: ferric citrate from Biovectra; silicified microcrystalline cellulose (Prosolv™ SMCC 50 and Prosolv SMCC HD90 which is
15 composed of microcrystalline cellulose, NF and colloidal silicon dioxide, NF) from JRS Pharma; pregelatinized starch, NF (Starch 1500) from Colorcon; Povidone, NF (Plasdone™ K-29/32) from ISP; hydroxypropyl cellulose, NF (Klucel™ EF) from Hercules; croscarmellose sodium, NF (Ac-Di-Sol™-SD-711) from FMC Biopolymer; and magnesium stearate, NF from Mallinckrodt.

20 The equipment used for the formulations included: FLM1 fluid bed from Vector Corporation of Marion, IA; Comil conical mill from Quadro Engineering of Millburn, NJ; GMX high shear granulator 4L bowl from Vector Corporation of Marion, IA; 2qt v-blender from Patterson Kelley of East Stroudsburg, PA; XL100 Pro tablet press from Korsch of South Easton, MA; capsule-shaped tooling from Elizabeth Carbide of Lexington, NC; and Sonic
25 sifter separator from Advantech Manufacturing of New Berlin, WI.

 The equipment used for the analytical testing of the formulations included: 8M Tablet Tester (hardness tester) from Dr. Schleuniger of Manchester, NH; Friabilator from VanKel of Palo Alto, CA; Flodex from Hanson Research of Chatsworth, CA; Bathless Disintegration System, Model 3106 and Bathless Dissolution System, Evolution 6100 from Distek of North
30 Brunswick, NJ; and Model 8453 Uv-Vis from Agilent of Santa Clara, CA.

High Shear Granulation

 A series of experiments were conducted to determine the ability to use a high shear granulator to make a tablet blend having suitable characteristics. Formulations 1-3 are shown below in Tables 1-3.

Table 1 (Formulation 1)

Component	mg/tablet	%w/w
Milled Ferric Citrate	1190.3	75.0
Silicified microcrystalline cellulose (Prosolv SMCC 50)	238.1	15.0
Croscarmellose sodium	47.6	3.0
Hydroxypropyl cellulose	95.2	6.0
Magnesium stearate	15.9	1.0
Total	1587.0	100.0

Table 2 (Formulation 2)

Component	mg/tablet	%w/w
Milled Ferric Citrate	1190.4	60.0
Silicified microcrystalline cellulose (Prosolv SMCC 50)	595.2	30.0
Croscarmellose sodium	59.5	3.0
Hydroxypropyl cellulose	119.0	6.0
Magnesium stearate	19.8	1.0
Total	1984.0	100.0

Table 3 (Formulation 3)

Component	mg/tablet	%w/w
Milled Ferric Citrate	1190.3	69.0
Silicified microcrystalline cellulose (Prosolv SMCC 50)	258.8	15.0
Croscarmellose sodium	86.3	5.0
Hydroxypropyl cellulose	172.5	10.0
Magnesium stearate	17.3	1.0
Total	1725.0	100.0

The manufacturing procedure for the Formulations 1-3 were as follows.

- 5 Milled ferric citrate, hydroxypropyl cellulose, silicified microcrystalline cellulose, and croscarmellose sodium were mixed for 2 minutes at 500 rpm in a GMX high shear granulator 4 L bowl. Deionized water was added at an approximate rate of 18 g/min over 10 minutes, while mixing at a rate of 900 rpm with a chopper speed of 1500 rpm. The final (peak) moisture content was measured to be 24.3%, 23.8%, and 24.4%, respectively. The granules
- 10 were dried in a FLM1 fluid bed for 5-8 minutes at an inlet temperature of 65°C. The moisture content after drying was measured to be 14.3%, 15.5%, and 15.9%, respectively. The granules were screened through a 16 mesh hand-screen, then through a 25 mesh hand screen to remove over-sized granules and clumps. The magnesium stearate was screened

through a 25 mesh hand-screen. Granules and magnesium stearate were blended for 2 minutes in a 2 quart v-blender. Tableting was performed on a Korsch tablet press with capsule shaped tooling.

It was found that the resulting tablet blends demonstrated poor flow through the hopper due to the irregular particle shape of the granules. Nonetheless, excellent tablets were able to be made using the tableting equipment.

Example 2:

Another series of experiments were conducted to determine whether a tablet could be formulated using a fluid bed granulation process:

Table 4 (Formulations 4 and 5)

Component	mg/tablet	%w/w
Milled Ferric Citrate	1190.7	90.0
Pregelatinized starch	119.1	9.0
Magnesium stearate	13.2	1.0
Total	1323.0	100.0

Manufacturing Procedure for Formulations 4 and 5 depicted in Table 4 are provided below as follows:

Milled ferric citrate was added to a FLM1 fluid bed granulator. For Formulation 4, pregelatinized starch was added as a 10% w/w solution at a spray rate that increased from 24 g/min to 52 g/min over the duration of the run. [Inlet Temp = 64-77°C; Product Temp = 25-35°C; Process Air = 29-35 CFM]. The final (peak) moisture content was measured to be 32.5%.

For Formulation 5, pregelatinized starch was added as a 10% w/w solution at an average spray rate of 40.8 g/min. [Inlet Temp = 69-75°C; Product Temp = 25-35°C; Process Air = 24-38 CFM]. The final (peak) moisture content was measured to be 30.0%.

The granules were dried for 7-10 minutes at an inlet temperature of 65°C. The moisture content after drying was measured to be 15.5% and 16.7%. Granules were milled through a Comil equipped with a 45R screen and square impeller at 1500 rpm. The magnesium stearate was screened through a 25 mesh hand-screen. Granules and magnesium stearate were blended for two minutes in a two quart V-blended. Tableting was performed on a Korsch tablet press with capsule shaped tooling.

The primary difference between the tablets of Formulations 4 and 5 was the disintegration time. The tablets of Formulation 5 had a slower disintegration time than the tablets of Formulation 4. These prototypes had no flow problems during tableting.

The powder properties of Formulations 1-5 were characterized as shown in Tables 5 and 6. All blends have excellent flow properties as measured by the Flodex.

Table 5. Powder Characterization of High Shear Blends

Measurement	Formulation 1	Formulation 2	Formulation 3
Bulk density	0.772 g/mL	0.618 g/mL	0.679 g/mL
Flodex	4	5	10

Table 6. Powder Characterization of Fluid Bed Blends

Measurement	Formulation 4	Formulation 5
Bulk density	0.647 g/mL	0.578 g/mL
Flodex	4	4

Experimental formulations of Formulations 1 and 5 were examined by Scanning Electron Microscopy (SEM) and both samples have a similar particle size range. While the particles of Formulation 1 appeared to have a bimodal distribution, both samples have distinct particle morphologies. Formulation 1, which was prepared by high shear granulation, has more sharp, oblong particles. Formulation 5, prepared by fluid bed granulation, has more soft, round particles. This difference is believed to have an impact on the flow properties observed during tableting.

The tablet properties of Formulations 1-5 were characterized as shown in Table 7 and Table 8. Compaction profiles were made of each formulation, graphically presented in Figure 1 (hardness), Figure 2 (friability), and Figure 3 (disintegration). Characterization data is presented only of the tablets prepared at the highest compaction force. Compression force is measured in kilo Newtons. Dissolution results are graphically presented in Figure 4 for Formulations 1 and 3-5.

For the hardness testing, the tablets were tested according to USP <1217> for hardness/breaking strength. For the friability testing, the tablets were tested following USP <1216> for friability. For the disintegration testing, six tablets were tested using a disintegration apparatus in deionized water at 37°C. For the dissolution testing, six tablets were tested for dissolution properties according to the conditions listed below. Tablet dissolution results were scaled to report 100% dissolution as a 1000 mg dose, correcting for actual average tablet weight, as needed.

Dissolution Conditions:

Dissolution Instrument: Distek Evolution 6100

Medium: pH 4.0 McIlvaine buffer

Apparatus USP: Apparatus II (paddle method); 100 rpm

Temperature: 37°C ± 0.5°C

Time: Samples taken at 5, 15, 30, and 60 minutes

UV-Vis Instrument: Agilent 8453 UV-Vis; 360 nm with 600 nm background correction.

Table 7. Characterization of High Shear Experiments (Formulations 1-3)

Measurement	Formulation 1	Formulation 2	Formulation 3
Weight variation	Average 1580.8 mg (0.5% RSD)	Average 1485.6 mg (0.4% RSD)	Average 1518.4 mg (0.7% RSD)
Thickness	Average 8.59 mm (0.2% RSD)	Average 8.37 mm (0.2% RSD)	Average 8.69 mm (0.4% RSD)
Hardness	18.1 kP (2.6% RSD)	19.5 kP (2.3% RSD)	21.5 kP (3.8% RSD)
Friability	0.19%	0.22%	0.26%
Disintegration	Average 5.8 minutes	Average 19.8 minutes	Average 3.0 minutes
Dissolution	48.2% in 60 minutes	---	49.7% in 60 minutes

Table 8. Tablet Characterization of Fluid Bed Experiments (Examples 4 and 5)

Measurement	Formulation 4	Formulation 5
Weight variation	Average 1286.5 mg (0.3% RSD)	Average 1313.2 mg (0.4% RSD)
Thickness	Average 7.18 mm (0.2% RSD)	Average 7.24 mm (0.2% RSD)
Hardness	Average 19.3 kP (3.2% RSD)	20.5 kP (7.4% RSD)
Friability	0.20%	0.23%
Disintegration	Average 7.7 minutes	Average 36.3 minutes
Dissolution	50.4% in 60 minutes	42.5% in 60 minutes

For the high shear prototypes (Formulations 1-3) incorporation of increased silicified microcrystalline cellulose (Formulation 1 and Formulation 2) improved compactibility, as shown by reduced compression forces required to achieve equivalent hardness. Also, incorporation of increased hydroxypropyl cellulose (Formulations 1, 2, and 3) improved compactibility, as shown by reduced compression forces required to achieve equivalent hardness.

Example 3

Additional development was conducted to achieve a balance between dissolution profile and acceptable tablet properties. The fluid bed granulation spray rate was varied step-wise using pregelatinized starch, which showed that in-process moisture content plays a role in dissolution profile and tablet properties.

Fluid Bed Granulation with Starch

Batches of Formulations 6-11 shown in Tables 9 and 10 were prepared using pregelatinized starch with target batch sizes of 1.0 kg.

Table 9. Formulation Formulations 6-8

Component	mg/tablet	%w/w
Milled Ferric Citrate	1190.7	90.0
Pregelatinized starch	119.1	9.0
Magnesium stearate	13.2	1.0
Total	1323.0	100.0

Table 10. Formulation Formulations 9-11

Component	mg/tablet	%w/w
Milled Ferric Citrate	1190.7	80.9
Pregelatinized starch	119.1	8.1
Silicified microcrystalline cellulose	147.2	10.0
Magnesium stearate	13.2	1.0
Total	1470.2	100.0

Formulations 6-11 were manufactured as follows:

Milled Ferric Citrate was added to a FLM1 fluid bed granulator. Pregelatinized starch was added as a 10% w/w solution using the granulation and drying parameters in Table 11.

All batches were dried at an inlet temperature of 65°C.

Table 11. Granulation Parameters

Parameter	Formulation 6 and 9	Formulations 7 and 10	Formulations 8 and 11
Spray rate	24.0 g/min	32.5 g/min	37.5 g/min
Inlet temp	69-79°C	72-75 °C	69-76 °C
Product temp	26-35°C	26-36 °C	26-35 °C
Process air	31-36 CFM	32-38 CFM	36-39 CFM
Final (peak) moisture	17.3%	23.4%	25.7%
Moisture after drying	14.8%	16.1%	17.5%
Drying time	2 minutes	5 minutes	7 minutes

Granules from Formulations 6, 7, 9 and 10 were screened through a 20 mesh hand-screen. Granules from Formulations 8 and 11 were milled through a Comil equipped with a 45R screen and square impeller at 1500 rpm, then screened through a 20 mesh hand-screen.

Two blends were prepared from each granulation. In the first blend, the magnesium stearate was screened through a 25 mesh hand-screen. Granules and magnesium stearate were blended for two minutes in a two quart V-blender. In the second blend, the magnesium stearate was screened through a 25 mesh hand-screen. Granules, silicified microcrystalline cellulose, and magnesium stearate were blended for two minutes in a two quart V-blender.

Tableting was performed on a Korsch tablet press with capsule shaped tooling on several of the prepared blends.

The resulting tablets of Formulations 6 and 9 had flow properties with Hausner ratio values equal to or less than 1.25 and/or Carr index values equal to or less than 25. In various embodiments, the Hausner ratio is equal to or less than 1.20. In further embodiments, the Hausner ratio is equal to or less than 1.20. In various embodiments, the Carr index is less than 25. In further embodiments, the Carr index is equal to or less than 20.

Excellent flow: Hausner ratio values about or less than 1.20 and Carr index values less than 20) but showed evidence that additional lubrication was needed to achieve better tableting results. The resulting tablets of Formulations 7, 8, 10 and 11 had excellent flow properties and made successful tablets.

The powder properties of Formulations 6-11 were characterized as shown in Tables 12 and 13. Formulations 7, 8, 10 and 11 have flow properties with Hausner ratios equal to or less than 1.20 and Carr index values less than 20 as measured by the Flodex, presumably due to the higher spray rates of those experiments. The bulk density of the starch granulation experiments increased as the spray rate increased.

Table 12. Powder Characterization of Fluid Bed Experiments

Measurement	Formulations 6 and 9	Formulations 7 and 10	Formulations 8 and 11
Bulk density	0.475 g/mL	0.531 g/mL	0.698 g/mL
Flodex	7	4	4

The tablet properties of Formulations 6-8 and 11 were characterized as shown in Table 13 and 14. Compaction profiles were made for each formulation and are graphically presented in Figure 5 (hardness), Figure 6 (friability) and Figure 7 (disintegration).

Characterization data is presented only of the tablets prepared at the highest compaction force. Dissolution results are graphically presented in Figure 8 for Formulations 6-8 and 11.

Table 13. Tablet Characterization of High Shear Formulations 6 and 7

Measurement	Formulation 6	Formulation 7
Weight variation	Average 1126.9 mg (0.4% RSD)	Average 1272.8 mg (0.4% RSD)
Thickness	Average 7.74 mm (0.2% RSD)	Average 8.00 mm (0.5% RSD)
Hardness	Average 11.2 kP (28.7% RSD)	27.2 kP (8.9% RSD)
Friability	2.23%	0.36%
Disintegration	Average 1.8 minutes	Average 3.9 minutes
Dissolution	99.9% in 60 minutes	95.7% in 60 minutes

Table 14. Tablet Characterization of Fluid Bed Formulations 8 and 11

Measurement	Formulation 8	Formulation 11
Weight variation	Average 1332.0 mg (0.3% RSD)	Average 1497.7 mg (0.3% RSD)
Thickness	Average 7.94 mm (0.1% RSD)	Average 8.72 mm (0.1% RSD)
Hardness	Average 21.1 kP (2.8% RSD)	26.1 kP (2.9% RSD)
Friability	0.28%	0.15%
Disintegration	Average 11.7 minutes	Average 8.3 minutes
Dissolution	55.8% in 60 minutes	65.6% in 60 minutes

- 5 Milled Ferric Citrate and croscarmellose sodium were added to a FLM1 fluid bed. Povidone was added as a 30% w/w solution (Formulation 12) and 20% w/w solution (Formulation 13) using the granulation and drying parameters in Table 15 to make granules. No drying was required.

Table 15. Granulation Parameters

Parameter	Formulation 12	Formulation 13
Spray rate	22.9 g/min	30.0 g/min
Inlet temp	55-60°C	52-58°C
Product temp	31-37°C	22-30°C
Process air	31-36 CFM	35-38 CFM
Final (peak) moisture	13.0%	17.3%

- 10 Granules were screened through a 20 mesh hand-screen. The magnesium stearate was screened through a 25 mesh hand-screen. Granules and magnesium stearate were blended for two minutes in a two quart V-blender.

- 15 Tableting was performed on a Korsch tablet press. During the tableting process, there was excessive sticking to the tooling. This sticking was believed to be addressable by use of different tooling or by varying the tableting parameters.

Example 4

Additional examples were formulated and analyzed. A summary of the results are provided below in Tables 16 and 17. Table 16 provides a summary of results for Formulations 14-20 using direct compression of the formulations. Table 17 provides a
5 summary of results for Formulations 21-29 using fluid bed granulation. These various formulations showed a variety of ranges of properties that could be useful depending upon the application, e.g., immediate release, extended release, and delayed release, with a minor amount of additional experimentation required for some of the formulations to ensure that suitable tablets are formed.

Table 16. Qualitative Results for Direct Compression Formulations

Experiment Reference	Dose Target	Formulation Summary	Results and Observations
Formulation 14	667 mg	91.9% Ferric Citrate, 7.3% Prosolv SMCC 50, 0.8% Magnesium Stearate	Tablets had some lamination, achieved 12.5 kP average hardness
Formulation 15	667 mg	91.9% Ferric Citrate, 7.3% Prosolv HD 90, 0.8% Magnesium Stearate	Friability equal to or less than 1.0% w/w.
Formulation 16	667 mg	87.0% Ferric Citrate, 7.3% Prosolv SMCC 50, 4.9% Povidone K-29/32, 0.8% Magnesium Stearate	Friability equal to or less than 1.0% w/w.
Formulation 17	500 mg	90.7% Ferric Citrate, 8.5% Prosolv HD 90, 0.8% Magnesium Stearate	Tablets show capping and lamination addressable with additional binder or varying the tableting parameters
Formulation 18	500 mg	90.7% Ferric Citrate, 8.0% Prosolv HD 90, 0.5% Povidone K-29/32, 0.8% Magnesium Stearate	Tablets show capping and lamination addressable with additional binder or varying the tableting parameters; long disintegration times
Formulation 19	500 mg	88.0% Ferric Citrate, 7.0% Avicel PH 200, 2.7% Povidone K-29/32, 1.5% Crospovidone XL, 0.8% Magnesium Stearate	Tablets show capping and lamination addressable with additional binder or varying the tableting parameters; disintegration time reduced to 1-3 minutes suitable for immediate release applications
Formulation 20	500 mg	87.0% Ferric Citrate, 7.0% Avicel PH 200, 3.7% Povidone K-29/32, 1.5% Crospovidone XL, 0.8% Magnesium Stearate	Tablets show reduced lamination that was addressable with additional binder or varying the tableting parameters, disintegration time 3-5 minutes suitable for immediate release applications

Table 17. Qualitative Results for Fluid Bed Granulation Formulations

Experiment Reference	Dose Target	Formulation Summary	Results and Observations
Formulation 21	500 mg	90.0% Ferric Citrate, 2.0% Povidone K-29/32, 2.0% Starch 1500, 5.2% Avicel PH 102, 0.8% Magnesium Stearate	Friability equal to or less than 1.0% w/w.
Formulation 22	500 mg	90.0% Ferric Citrate, 4.0% Starch 1500, 5.2% Avicel PH 102, 0.8% Magnesium Stearate	Acceptable tablet properties with additional development work needed for tablet integrity
Formulation 23	500 mg	90.0% Ferric Citrate, 9.0% Starch 1500, 1.0% Magnesium Stearate	Tablets have disintegration to be more than 15 minutes.
Formulation 24	500 mg	90.0% Ferric Citrate, 4.0% Starch 1500, 5.2% Avicel PH 102, 0.8% Magnesium Stearate	Tablets have disintegration to be more than 15 minutes.
Formulation 25	500 mg	80.0% Ferric Citrate, 8.0% Starch 1500, 11.0% Avicel PH 200, 1.0% Magnesium Stearate	Tablets have disintegration to be more than 15 minutes.
Formulation 26	500 mg	90.0% Ferric Citrate, 9.0% Starch 1500, 1.0% Magnesium Stearate	Tablets have disintegration to be more than 15 minutes.
Formulation 27	500 mg	85.0% Ferric Citrate, 8.5% Starch 1500, 5.5% Avicel PH 200, 1.0% Magnesium Stearate	Tablets have disintegration to be more than 15 minutes.
Formulation 28	1000 mg	84.9% Ferric Citrate, 5.6% Starch 1500, 8.6% Avicel PH 200, 1.0% Magnesium Stearate	Granulation very dense
Formulation 29	1000 mg	89.5% Ferric Citrate, 5.9% Starch 1500, 3.6% Avicel PH 200, 1.0% Magnesium Stearate	Acceptable tablet properties with tableting and coating successful

Example 5

Tables 18a and 18b provide Formulation 30 and 31 for an exemplary ferric citrate
5 drug product.

Table 18a. Formulation 30 for a Ferric Citrate Drug Product

Material Description	Theoretical kg/Batch	% w/w
Ferric Citrate	14.89	87.6
Pregelatinized Starch	1.70	10.0
Calcium Stearate	0.406	2.4
Purified Water	15.30*	N/A**
Core Tablet Total	17.00	100.0
Opadry Purple 03K100000	0.51	15.0
Purified Water	2.89*	85.0**
Coated Tablet Total	17.5	100.0

*Purified water is removed during the drying phase.

5

Table 18b: Formulation 31 for a Ferric Citrate Drug Product

Material Description	Theoretical Kg/Batch	% w/w
Ferric Citrate	14.87	85.0
Silicified Microcrystalline Cellulose	0.70	4.0
Pregelatinized Starch	1.58	9.0
Calcium Stearate	0.35	2.0
Purified Water	14.18	N/A*
Core Tablet Total	17.5	100.0
Opadry Purple 03K100000	0.51*	15.0
Purified Water	2.89*	85.0**
Coated Tablet Total	18.0	100.0

Table 19 provides a proposed ferric citrate drug product formulation that can be used in the manufacturing process described below.

10

Table 19. Formulation 32

Material Description	Theoretical 100 kg/Lot	% w/w to Core Tablet	% w/w Coated Tablet
Ferric Citrate	80.0 - 90.0	80.0 - 90.0	76.2 - 88.2
Pregelatinized Starch	8.0 - 15.0	8.0 - 15.0	7.6 - 14.7
Calcium Stearate	2.0 - 3.0	2.0 - 3.0	1.9 - 2.9
Purified Water	N/A*	N/A*	N/A*
Core Tablet Total	100.0	100.0	N/A*
Opadry Purple 03K100000	5.3	15.0	2.0 - 5.0
Purified Water	30.0*	85.0*	N/A*
Coated Tablet Total	35.3	100.0	100.0

*Purified water is removed

- (1) or other binders as listed in the patent
- (2) or other lubricants as listed in the patent
- (3) or other coating system as listed in the patent

5 **Example 6**

 The drug product tablet was produced using fluid bed granulation of the screened API with a binder suspension of pregelatinized starch, targeting for a moisture content after granulation of approximately 13-20%. The granulated active was subsequently blended with
10 screened calcium stearate and the mix compressed to form a tablet core. The tablet was robust with friability equal to or less than 1.0% w/w, hardness from 8 – 20 kP, disintegration equal to or less than 15 min, and compression force about 3.5 – 5.0 kN, with a main force 5 – 20 kN. It will be recognized that various embodiments are within the ranges of one or more of each of these parameters.

15 The weight of individual tablets can depend upon the final dosage to be produced; e.g., 125mg, 250mg, 500mg, 667mg, 750mg and 1,000mg of Ferric citrate. The process is capable of consistently producing tablets within a specification of $\pm 5\%$ of target. The tablet thickness and hardness meet the specified acceptance criteria. The tablets are coated to a target weight gain of approximately 2% to 5% using an Opadry suspension or equivalent in a
20 perforated pan coater.

 The production results demonstrate the selected formulation and process is capable of producing robust tablets meeting the specified criteria. First, ferric citrate was passed through a screening mill. A granulation drug binder suspension was then prepared by adding purified water to a stainless steel mixing kettle, then adding pregelatinized starch to the
25 purified water and mix. Granulated particles were formed by screening ferric citrate through a fluid granulator. The pregelatinized starch binder suspension was sprayed into the fluidized product bed. At the completion of binder addition the granulation is dried.

 The dried granules were charged into a diffusion mixer. Calcium stearate was screened and added to the granulation in the diffusion mixer. The granules and lubricant were
30 mixed.

 The lubricated granules were compressed into tablets. Tablets were collected in intermediate bulk containers. An aqueous film coating suspension was prepared in a stainless steel kettle and mixer,. The tablets were charged into a fully perforated pan coater, and the coating suspension was sprayed onto the cascading product bed. Upon completion of the
35 spraying step the tablets were dried. Film coated tablets were discharged into intermediate

bulk containers. The film coated tablets were packaged in HPDE bottles with desiccant and child resistant foil induction seal cap.

Example 7

Ferric citrate tablets were formulated as described above. Tablet formulations 33 and 34 are depicted in Tables 20 and 21.

Table 20: Formulation 33

Material Description	Target kg/Batch	Theoretical 100 kg/Lot	% w/w Individual	% w/w Coated Tablet
Ferric Citrate	14.9	80.0 - 90.0	80.0 - 90.0	76.2 - 88.2
Pregelatinized Starch	1.7	8.0 - 15.0	8.0 - 15.0	7.6 - 14.7
Calcium Stearate (1)	0.4	1.0 - 3.0	1.0 - 3.0	0.9 - 2.9
OR - Sodium Stearyl Fumarate (1)	0.4	2.0 - 3.0	2.0 - 3.0	1.9 - 2.9
Purified Water	15.3*	72.0-135.0*	*	*
Core Tablet Total	17.0	100.0	100.0	N/A*
Opadry Purple	0.9	5.3	15.0	2.0 - 5.0
Purified Water	5.1*	30.0*	85.0*	N/A*
Coated Tablet Total	17.5 to 17.9	35.3	100.0	100.0

(1) – use either calcium stearate or sodium stearyl fumarate as lubricant

*Purified water is removed

Table 21: Formulation 34

Material Description	Target kg/Batch	Theoretical 100 kg/Lot	% w/w Individual	% w/w Coated Tablet
Ferric Citrate	14.9	80.0 - 90.0	80.0 - 90.0	76.2 - 88.2
Pregelatinized Starch	1.6	8.0 – 12.0	8.0 – 12.0	7.6 – 11.5
Silicified Microcrystalline Cellulose	0.7	3.0 – 5.0	3.0 – 5.0	2.5 – 4.5
Calcium Stearate (1)	0.4	1.0 – 3.0	1.0 – 3.0	0.9 – 2.9
OR – Sodium Stearyl Fumarate (1)	0.4	2.0 – 3.0	2.0 – 3.0	1.9 – 2.9
Purified Water	15.3*	72.0-135.0*	*	*
Core Tablet Total	17.6 to 18.0	100.0	100.0	N/A*
Opadry Purple 03K100000	0.9	5.3	15.0	2.0 – 5.0
Purified Water	5.1*	30.0*	85.0*	N/A*
Coated Tablet Total	17.8 to 18.9	35.3	100.0	100.0

(1) – use either calcium stearate or sodium stearyl fumarate as lubricant

*Purified water is removed

5 Example 8

A ferric citrate tablet was made under conditions in which granulation was conducted by allowing the LOD water % to increase above 25%.

Pharmaceutical grade ferric citrate was added into a fluid bed granulator. Pregelatinized starch binder suspension (Pregelatinized starch + water) was sprayed into the fluidized product bed. The water moisture level of the formulation was allowed to exceed 25% by LOD (loss on dried method).

In embodiments in which the moisture of the formulation was brought to the level above 25% LOD at any point resulted in a substantially lower surface area per gram of particle.

Referring Table 22, the increase the moisture provided during manufacturing increased above 20% at 120 minutes, increased to 27.87% at 170 minutes.

Table 22 Granulation Operating Parameters

Time	Rate (g/min)	Pump Speed (rpm)	Inlet Air (scfm)	Inlet Temp (°C)	Product Temp (°C)	Atom Air (psi)	LOD (%)	Exhaust Temp (°C)
0	-	-	145	42	35.8	65.0	11.85	30.6
10	87.7	30	150	61.6	30.0	65.0	12.82	28.4
20	71.2	30	153	63.5	28.2	65.0	13.02	26.6
30	76.2	30	153	63.1	27.5	64.7	13.18	25.8
40	77.7	30	144	63	27.1	65.1	15.19	25.4
50	75.9	30	146	63.1	27.0	65.1	15.7.0	25.3
60	79.6	30	147	63.0	26.8	65.1	15.74	25.2
71	80.0	30	144	62.9	26.7	65.1	-	25.1
80	83.4	33	149	63.0	26.7	65.1	17.31	25.1
90	90.5	33	151	63.0	26.5	65.1	18.49	25.0
100	90.4	33	152	63.0	26.5	65.1	18.64	24.9
110	90.5	33	153	63.0	26.4	65.1	18.99	24.8
120	90.5	33	150	63.0	26.4	65.1	22.89	24.8
130	90.4	33	144	63.0	26.3	65.1	22.47	24.8
141	91.1	33	153	63.0	26.3	65.1	24.25	24.7
150	90.2	33	152	63.0	26.2	65.1	25.41	24.7
160	91.8	33	153	62.9	26.2	65.0	26.03	24.7
170	89.6	33	154	63.0	26.2	65.1	27.89	24.7
180	90.7	33	149	63.0	26.2	65.1	27.47	24.7
190	-	-	147	63.0	26.4	-	26.76	24.7
200	-	-	150	63.0	26.8	-	25.00	25.0
210	-	-	154	63.1	27.2	-	22.37	25.1
220	-	-	153	63.1	27.8	-	21.32	25.2
230	-	-	149	63.1	29.0	-	18.68	25.7
240	-	-	153	63.1	30.7	-	17.55	26.5
						Final LOD	16.69	

The measured surface area of two samples prepared using the above formulation is depicted in Table 23. The surface areas of the formulations were 0.12 m²/g and 0.20 m²/g.

Table 23

Sample	Sample 1 BET Surface Area (m ² /g)	Sample 2 BET Surface Area (m ² /g)
Pre-granulation(API+ProSolv)	27.99	32.34
PostGranulation	0.12	0.20

The mean surface area per unit mass ratios of the two samples was 0.12 and 0.20 m²/g, respectively.

Example 9

A ferric citrate tablet was prepared by keeping granules at an LOD % water concentration less than 25% during granulation.

Pharmaceutical grade ferric citrate was added into a fluid bed granulator.

- 5 Pregelatinized starch binder suspension (Pregelatinized starch + water) was sprayed into the fluidized product bed. With reference to Table 24, the moisture level of the formulation was maintained at below 20% by LOD (loss on dried method) at all times during the spraying process. The surface area of the resulting formulation was greater than 10 square meters per gram.

10

Table 24

Time (min)	Spray Rate (g/min)	Pump Speed (rpm)	Inlet Air (SCFM)	Inlet Temp (°C)	Product Temp (°C)	Atom Air (psi)	Exhaust Temp (°C)	LOD (%)
0	-	-	149	55.4	39.8	-	44.5	12.05
10	86.1	31	153	70.3	36.0	65.0	39.6	12.44
20	88.2	31	152	70.1	32.0	64.9	35.4	13.01
30	87.9	31	146	69.8	30.0	65.1	36.6	13.38
40	90.1	31	153	70.0	28.9	64.8	30.6	13.80
50	85.2	31	151	70.0	28.6	65.1	29.8	14.36
60	87.5	31	144	70.0	28.2	65.1	28.9	15.03
70	89.0	31	153	72.5	28.1	65.1	28.4	16.49
80	87.0	31	145	75.9	28.4	65.1	28.3	16.34
90	88.7	31	153	78.5	28.9	65.1	28.5	17.25
100	94.0	31	149	80.3	29.2	64.9	28.5	17.43
110	82.5	31	153	80.2	29.2	65.1	28.4	19.60
120	78.3	25	152	79.9	30.0	64.9	28.9	19.08
130	66.4	25	153	79.9	29.2	64.9	28.4	19.24
141	66.3	25	152	79.8	29.8	65.1	28.6	19.29
150	66.1	25	153	80.2	29.7	64.9	28.7	18.44
160	65.7	25	152	80.1	29.6	65.1	28.5	18.43
170	66.1	25	153	80.1	30.0	65.1	28.8	18.85
181	57.7	25	152	79.9	29.4	64.8	28.4	-
191	76.9	25	154	80.0	29.4	65.0	28.3	16.70
200	63.9	25	153	80.0	30.2	65.0	28.7	18.64
210	-	-	150	74.6	31.0	-	28.0	16.97
220	-	-	150	80.7	37.1	-	31.7	14.95
							Final LOD =	13.30

The results showed a reduced surface area between the pre-granulated and granulated materials (see the Table 25). The results are depicted in Table 25, Sample 1. Table 25,

- 15 samples 2 and 3 also show a surface area of over 10 m²/g, which corresponds to rapid

immediate release formulation characteristics as described herein. The difference in granule particle size is nearly two orders of magnitude over granules that were prepared with increased water as measured by LOD%.

Table 25

Sample	Sample 1 BET Surface Area (m ² /g)	Sample 2 BET Surface Area (m ² /g)	Sample 3 BET Surface Area (m ² /g)
Pre-granulation(API+ProSolv)	28.87	28.87	28.87
PostGranulation	11.85	14.03	10.18
PTLReportNumber	19005	19005	19005

5

A significant increase in particle surface area corresponding to a reduction in particle size. Tablets with higher granular surface area faster dissolution rate when compared to tablets prepared with a lower surface area per unit weight.

10 Calcium stearate and sodium stearyl fumarate were added as lubricants. The quantity used in the formula are beyond the quantities recommended in the art (e.g. Handbook of Pharmaceutical Excipients fifth edition). 0.5% w/w of sodium stearyl fumarate 2.4% w/w of calcium stearate was used.

Example 10

15

A ferric citrate tablet was produced for clinical study as described above. The quantities of tablet components used are depicted in Table 26.

Table 26

Material Description	Target kg/Batch	% w/w Individual
Ferric Citrate	14.89	87.6
Pregelatinized Starch	1.70	10.0
Calcium Stearate (1)	0.406	2.4
Purified Water	15.30	N/A
Core Tablet Total	17.00	100.0
Opadry Purple	0.51	15.0
Purified Water	2.89	85.0
Coated Tablet Total	17.5	100.0

Pregelatinized starch was sprayed into a chamber maintained at inlet temperature and product temperature. The LOD % water at every stage of preparation was maintained under 20%.

The parameters used during the formulation are disclosed in Table 27.

Table 27

Time (min)	Spray Rate (g/min)	Pump Speed (rpm)	Inlet Air (SCFM)	Inlet Temp (°C)	Product Temp (°C)	Atom Air (psi)	Exhaust Temp (°C)	LOD (%)
0	-	38	150	61.5	42.6	60	11.24	41.3
10	107.6	38	151	63.0	31.3	60	12.4	34.5
20	109.1	38	151	63.1	27.1	60	13.32	29.5
30	109.5	38	150	63.0	26.1	60	14.37	27.5
40	109.5	38	151	63.0	25.5	60	15.64	26.4
50	109.6	38	151	62.9	25.3	60	16.99	25.7
60	109.5	38	152	69.4	25.9	60	17.66	25.5
71	109.9	38	153	72.8	26.9	60	19.35	26.3
80	94.7	30	153	72.3	26.9	60	17.05	26.3
90	91.0	35	151	71.7	27	60	19.66	26.3
100	88.5	30	152	72.1	27.1	60	19.57	26.3
110	81.7	30	150	73.3	27.4	60	18.88	26.4
120	85.7	33	153	73.2	27.7	60	16.39	26.6
130	97.9	35	149	72.4	27.4	60	18.87	26.5
141	94.5	33	152	72.0	27.4	60	18.78	26.3
150	93.3	34	153	71.9	27.3	60	18.62	26.3
160	93.4	34	152	71.8	27.5	60	18.30	26.3
170	95.6	34	154	72.2	27.5	60	19.49	26.4
180	-	-	151	71.9	29.5	-	16.71	26.8

5

The targeted peak moisture between 19 – 20 % (LOD) was achieved with a moisture content of 19.66% (LOD). Table 28 and Table 29 summarize the physical properties after the granulation step and after the tableting and drying steps.

10

Table 28: Granulation Characteristics

ScreenSize	%Retained
35(500 μ m)	0.0
45(355 μ m)	1.3
60(250 μ m)	11.1
80(180 μ m)	16.2
120(125 μ m)	19.4
170(90 μ m)	16.0
230(63 μ m)	16.3
Pan	18.8

Table 29: Final blend (post-tableting and drying) characteristics

BulkDensity(g/ml)	0.460
TappedDensity(g/ml)	0.566
HausnerRatio	1.23
CarrIndex	19

Table 30 and Table 31 summarize the final blend characteristics of the formulations.

5 **Table 30: Final Blend Characteristics**

ScreenSize	% Retained
35(500 μ m)	0.0
45(355 μ m)	0.8
60(250 μ m)	10.8
80(180 μ m)	16.6
120(125 μ m)	20.3
170(90 μ m)	17.2
230(63 μ m)	15.6
Pan	17.0

Table 31: Test Results

BulkDensity(g/ml)	0.436
TappedDensity(g/ml)	0.573
HausnerRatio	1.31
CarrIndex	24

Table 32:

Attribute or Setting	Start	Middle	End
PressMainForce(kN)	9.9	9.9	-
PressPreForce(kN)	3.5	4.0	-
PressSpeed(rpm)	28.69	28.69	-
Friability(%)	0.2	-	-
Disintegration(seconds)	88	95	105

10

Table 33

Characteristic	Weight	Thickness	Hardness
Mean	1161	7.709	15.7
StandardDeviation	9.39	0.029	1.13
MinIndividual	1150	7.680	13.8
MaxIndividual	1186	7.800	18.0
RSD	0.81	0.38	7.20
Cpk	1.88	2.21	1.26

15

The compression data demonstrates that the subject formulation and process were capable of producing a robust tablet with rapid disintegration. The Cpk value for individual tablet weight demonstrates the process was capable of consistently producing tablets within a specification of $\pm 5\%$ of target. The tablet thickness and tablet hardness met the specified acceptance criteria.

Coating and Drying Operating Parameters:

The Opadry coating suspension was prepared to 15 % solids content by weight. The theoretical weight gain for the subject batch was 3 %. The film coating was a non-functional component used for aesthetics purposes only and therefore the actual weight gain was not critical to drug performance. The process sprayed to the theoretical quantity of coating suspension and not to a specific weight gain (an efficiency factor was not used). The average coated tablet weight post drying 1110 mg.

The operating parameters in Table 34 were used during the coating process:

Table 34

Time (min.)	AirFlow (cfm)	Inlet Temp (°C)	Dew Point (°C)	Exhaust Temp (°C)	Spray Rate (g/min)	Atom Air (psi)	Pan Speed (rpm)
0	308	55.0	4.9	33.2	45	37	10
15	317	46.0	5.6	36.4	48	37	10
30	307	45.1	6.3	37.3	44	37	10
45	309	50.4	7.6	34.6	40	37	10
60	307	44.4	7.6	36.7	51	37	10
75	310	52.9	7.5	37.3	53	37	10

The operating parameters in Table 35 were used during the final tablet drying process:

Table 35

Time (min)	Air Flow (cfm)	Inlet Temp (°C)	DewPoint (°C)	Exhaust Temp(°C)	%Water (LOD)
0	503	70.2	7.3	50.6	13.19
15	504	69.7	7.2	63.3	11.93
30	494	69.6	7.2	65.4	11.33
45	502	69.6	7.0	66.3	11.14
60	500	70.4	6.8	67.0	10.14
75	502	80.1	7.0	73.0	9.73
90	501	80.2	7.0	74.5	9.59
105	505	79.7	6.8	75.4	8.96
120	509	81.1	6.8	75.7	8.78
135	510	81.2	6.6	76.2	8.21
150	505	81.1	6.7	76.5	7.88

The dissolution profiles demonstrate that higher moisture levels in the tablet can reduce the dissolution rate over time. Tablets with high moisture content exposed to high temperature experienced accelerated reductions in dissolution rate. The post dried tablet, which had an end moisture content of 8.84 % (LOD), did not experience the same reduction in dissolution rate. The tablets containing high moisture level and calcium stearate experienced the greatest reduction in dissolution rate.

The core and coated tablets containing calcium stearate had slightly higher moisture contents (~15 % LOD) when compared to the core tablets containing sodium stearyl fumarate (~14 % LOD). Without wishing to be held to a particular theory or mode of action, this could be contributing to the difference in the observed dissolution rates. The final moisture content of the tablet and moisture in the tablet during manufacture appear to contribute to the immediate release characteristics and long term stability of the tablet.

The one month stability profile of pre-dried and post dried tablets stability were measured. The stability included both 25°C/60 % RH and 40°C/75% RH conditions. All samples were placed into HDPE bottles (0.025" wall thickness) with a foil induction seal cap, and a small portion of the study included bottles with desiccants. The following charts summarize the informal stability data.

With reference to Figure 9, the immediate dissolution rate (greater than 80% at 60 minutes after administration) of tablets exposed to the post-dry process was maintained. The dissolution rate reduced dramatically after one week at in the absence of the post-dry process.

Example 11: Clinical Study of Ferric Citrate Dosage Forms

A protocol for performing clinical studies of a ferric citrate drug formulation as described above is provided as follows.

The protocol includes a 6-Week Feasibility Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients with End-Stage Renal Disease (ESRD). The objective of the study is to determine the potential efficacy as a dietary phosphate binder and tolerability of KRX-0502 (ferric citrate) in controlling and managing serum phosphorus levels in patients with end-stage renal disease (ESRD) and monitoring the change in serum phosphorus from baseline to end of treatment after a four week treatment period.

The study design includes conducting the study of the drug in patients with ESRD on thrice weekly hemodialysis. Approximately 24 patients (twelve diabetic and twelve non-diabetic patients) will be initiated on study drug over two to three weeks.

The study consists of five periods: Screening, Washout, Study Drug Initiation, Treatment, and Final Visit. The two-week washout period is immediately followed by a six-week treatment period. The duration of the clinical trial is approximately three to four months with approximately two to three weeks being allocated for patient screening, washout, and initiation of the study drug.

The study population includes all ESRD patients on thrice weekly hemodialysis for at least three months prior to the Study Drug Initiation Visit (Visit 3) who are currently taking at least three tablets/capsules per day of calcium acetate, calcium carbonate, lanthanum

carbonate or sevelamer (hydrochloride or carbonate) or any combination of these agents will be eligible for enrollment. Approximately twelve patients will be diabetic and twelve patients will be non-diabetic. Approximately 24 to 48 patients will be screened to initiate approximately 24 patients on study drug. All patients will be recruited from 2-4 sites.

5 The study for the drug administration includes initiating approximately 24 patients on KRX-0502 (ferric citrate) following a two week washout period from their current phosphate binder and monitoring the serum phosphorus level during the study. The target level of serum phosphorus is approximately 3.5 to 5.5 mg/dL. The serum phosphorus levels will be checked weekly during the washout period and during the visits 4, 5, 6, and at the Final Visit
10 (Visit 7) of the treatment period

The KRX-0502 dosage is determined by initiating all patients on the study drug with a fixed dosage of 6 tablets per day with each tablet of ferric citrate containing 210 mg of ferric iron as ferric citrate (approximately 720 mg of ferric iron as ferric citrate) and titrating the blood samples of the patients at Visits 4, 5, and 6 as follows:

15 For a serum phosphorus level from 3.5-5.5 mgs/dL of the blood, no action is required, for a rise to > 5.6-6.9mgm/dL, the drug dosage is increased by one tablet per day and for a rise to 6.9 mg/d, the dosage is increased to 3 tablets per day to a maximum of 12 tablets/day.

Patients take the study drug orally with meals or snacks or within one hour after their meals or snacks. Patients are instructed not to take the study drug if greater than one hour
20 has passed since the ingestion of their meals or snacks. Some patients can require a different distribution in tablets in a given day due to snacks or missed meals. For example, if the patient is receiving a starting dose of 6 g/day that patient can be taking 2 tablets with breakfast, 2 with lunch, and 2 with dinner and can be switched to 1 with breakfast, 1 with a morning snack, 1 with lunch, 1 with a afternoon snack and 2 with dinner if diet dictates.

25 The second phase of the study in the statistical plan, the drug efficacy study, assesses the tolerability and safety of the study drug. Drug safety is assessed by recording and monitoring adverse events, reviewing concomitant medication use, conducting brief physical examinations (weight, blood pressure and heart rate), and obtaining sequential blood chemistries (including serum phosphorus, serum calcium and selected iron parameters) and
30 rates of adverse events and changes in laboratory parameters.

While several particular forms of the disclosure have been illustrated and described, it will be apparent that various modifications and combinations of the disclosure detailed in the text and drawings can be made.

For example, references to materials of construction, methods of construction, specific

dimensions, shapes, utilities or applications are also not intended to be limiting in any manner and other materials and dimensions could be substituted.

What is Claimed is:

1. A ferric citrate tablet comprising:
 - (a) a core comprising approximately 65% to approximately 92% by weight of ferric citrate and approximately 4.5% to approximately 30% by weight of a binder; and
 - (b) a coating,
 wherein the tablet has a friability equal or less than 1% w/w, and wherein at least 80% of the ferric citrate is dissolved in less than or equal to 60 minutes.
2. The ferric citrate tablet of claim 1, wherein the dissolving rate is measured by test method USP <711>.
3. The ferric citrate tablet of claim 1, wherein the moisture content of the tablet is less than 15% by loss of drying (LOD).
4. The ferric citrate tablet of claim 1, wherein the moisture content of the tablet is less than 10% by loss of drying (LOD).
5. The ferric citrate tablet of claim 1, wherein the moisture content of the tablet is less than 9% by loss of drying (LOD).
6. The ferric citrate tablet of any one of claims 1 to 5, wherein the binder comprises one or more of hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), sodium alginate, alginic acid, guar gum, acacia gum, xanthum gum, carbopol, cellulose gum (carboxymethyl cellulose), ethyl cellulose, maltodextrin, PVP/VA, povidone, microcrystalline cellulose, starch (partially or fully pregelatinized starch) and methyl cellulose.
7. The ferric citrate tablet of any one of claims 1 to 5, wherein the binder is pregelatinized starch.
8. The ferric citrate tablet of any one of claims 1 to 7, wherein the core comprises a

lubricant.

9. The ferric citrate tablet of any one of claims 1 to 7, wherein the core comprises approximately 0.5% to approximately 3% by weight of a lubricant.

10. The ferric citrate tablet of claim 8 or 9, wherein the lubricant is magnesium stearate, calcium stearate, sodium stearyl fumarate, or a combination thereof.

11. The ferric citrate tablet of claim 8 or 9, wherein the lubricant is calcium stearate.

12. The ferric citrate tablet of any one of claims 1 to 11, wherein the core further comprises a disintegrant.

13. The ferric citrate tablet of any one of claims 1 to 11, wherein the core further comprises approximately 1.5% to approximately 15% by weight of a disintegrant.

14. The ferric citrate tablet of claim 12 or 13, wherein the disintegrant is croscarmellose sodium, croppovidone, sodium starch glycolate or starch.

15. The ferric citrate tablet of any one of claims 1 to 14, wherein the core of the tablet comprises approximately 70% to approximately 92% by weight of ferric citrate.

16. The ferric citrate tablet of any one of claims 1 to 14, wherein the core of the tablet comprises approximately 80% to approximately 92% by weight of ferric citrate.

17. The ferric citrate tablet of any one of claims 1 to 14, wherein the core of the tablet comprises approximately 90% to approximately 92% by weight of ferric citrate.

18. The ferric citrate tablet of any one of claims 1 to 14, wherein the core of the tablet comprises approximately 80% to approximately 90% by weight of ferric citrate.

19. The ferric citrate tablet of any one of claims 1 to 14, wherein the core of the tablet

comprises approximately 85% to approximately 92% by weight of ferric citrate.

20. The ferric citrate tablet of any one of claims 1 to 19, wherein the tablet comprises approximately 1000 mg of ferric citrate.

21. The ferric citrate tablet of any one of claims 1 to 20, wherein the tablet has a disintegration time equal to or less than 15 minutes.

22. A ferric citrate tablet containing approximately 210 mg of ferric iron, wherein the tablet comprises:

(a) a core comprising approximately 87.6% by weight of ferric citrate, approximately 10% by weight of pregelatinized starch, and approximately 2.4% by weight of calcium stearate; and

(b) a coating,

wherein the tablet has a friability equal or less than 1% w/w and a disintegration time less than 15 minutes, and wherein at least 80% of the ferric citrate is dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is 8.84% by loss of drying (LOD).

23. Use of the ferric citrate tablet of any one of claims 1 to 22 for the prophylaxis or treatment of hyperphosphatemia in a patient.

24. Use of the ferric citrate tablet of any one of claims 1 to 22 for formulating a medicament for the prophylaxis or treatment of hyperphosphatemia in a patient.

25. The ferric citrate tablet of any one of claims 1 to 22 for use in the prophylaxis or treatment of hyperphosphatemia in a patient.

26. The ferric citrate tablet of any one of claims 1 to 22 for use in formulating a medicament for the prophylaxis or treatment of hyperphosphatemia in a patient.

27. Use of the ferric citrate tablet of any one of claims 1 to 22 for formulating a medicament for controlling serum phosphorus levels in an end-stage renal disease patient.
28. Use of the ferric citrate tablet of any one of claims 1 to 22 for controlling serum phosphorus levels in an end-stage renal disease patient.
29. The use of claim 27 or 28, wherein the patient is on hemodialysis.
30. The ferric citrate tablet of any one of claims 1 to 22 for use in controlling serum phosphorus levels in an end-stage renal disease patient.
31. The ferric citrate tablet of any one of claims 1 to 22 for use in formulating a medicament for controlling serum phosphorus levels in an end-stage renal disease patient.
32. The ferric citrate tablet of claim 30 or 31, wherein the patient is on hemodialysis.
33. A method for producing a ferric citrate tablet comprising (i) a core comprising approximately 65% to approximately 92% by weight of ferric citrate, approximately 4.5% to approximately 30% by weight of binder, and approximately 0.5% to approximately 3% by weight of lubricant, and (ii) a coating, wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes, and wherein the method comprises:
- (a) adding ferric citrate to a pre-heated fluid bed processor and spraying binder to produce granules, wherein a loss on drying (LOD) percentage during the granulation process is less than 25%;
 - (b) drying the granules to the LOD percentage of between 15% to 17%;
 - (c) blending the dried granules with lubricant;
 - (d) compressing the blend into tablets; and
 - (e) coating the tablets.
34. A method for producing a ferric citrate tablet comprising (i) a core comprising approximately 65% to approximately 92% by weight of ferric citrate, approximately 4.5% to

approximately 30% by weight of binder, and approximately 0.5% to approximately 3% by weight of lubricant, and (ii) a coating, wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes, and wherein the method comprises:

- (a) adding ferric citrate to a pre-heated fluid bed processor and spraying binder to produce granules, wherein a loss on drying (LOD) percentage during the granulation process is less than 25%;
- (b) drying the granules to the LOD percentage of less than 17%;
- (c) blending the dried granules with lubricant;
- (d) compressing the blend into tablets; and
- (e) coating the tablets.

35. The method of claim 34, wherein the granules are dried to an LOD percentage of less than 15% in step (b).

36. The method of claim 35, wherein the granules are dried to an LOD percentage of between 10% to 15% in step (b).

37. A method for producing a ferric citrate tablet comprising (i) a core comprising approximately 65% to approximately 92% by weight of ferric citrate, approximately 4.5% to approximately 30% by weight of binder, and approximately 0.5% to approximately 3% by weight of lubricant, and (ii) a coating, wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes, and wherein the method comprises:

- (a) blending dried granules with lubricant, wherein the dried granules comprise ferric citrate and binder and wherein the dried granules have a loss on drying (LOD) percentage of between 15% to 17%;
- (b) compressing the blend into tablets; and
- (c) coating the tablets.

38. A method for producing a ferric citrate tablet comprising (i) a core comprising approximately 65% to approximately 92% by weight of ferric citrate, approximately 4.5% to approximately 30% by weight of binder, and approximately 0.5% to approximately 3% by

weight of lubricant, and (ii) a coating, wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes, and wherein the method comprises:

- (a) blending dried granules with lubricant, wherein the dried granules comprise ferric citrate and binder and wherein the dried granules have a loss on drying (LOD) percentage of less than 17%;
- (b) compressing the blend into tablets; and
- (c) coating the tablets.

39. The method of claim 38, wherein the dried granules have an LOD percentage of less than 15% in step (a).

40. The method of claim 39, wherein the dried granules have an LOD percentage of between 10% to 15% in step (a).

41. The method of any one of claims 33 to 36, wherein the method further comprises (f) drying the coated tablets to an LOD percentage of between 5% to 14%.

42. The method of any one of claims 33 to 36, wherein the method further comprises (f) drying the coated tablets to an LOD percentage of less than 10%.

43. The method of any one of claims 33 to 36, wherein the method further comprises (f) drying the coated tablets to an LOD percentage of between 5% to 10%.

44. The method of any one of claims 33 to 36, wherein the method further comprises (f) drying the coated tablets to an LOD percentage of less than 9%.

45. The method of any one of claims 37 to 40, wherein the method further comprises (d) drying the coated tablets to an LOD percentage of between 5% to 14%.

46. The method of any one of claims 37 to 40, wherein the method further comprises (d) drying the coated tablets to an LOD percentage of less than 10%.

47. The method of any one of claims 37 to 40, wherein the method further comprises (d) drying the coated tablets to an LOD percentage of between 5% to 10%.

48. The method of any one of claims 37 to 40, wherein the method further comprises (d) drying the coated tablets to an LOD percentage of less than 9%.

49. The method of any one of claims 33 to 48, wherein the dissolving rate is measured by test method USP <711>.

50. The method of any one of claims 33 to 49, wherein the granules have a mean surface area to mass ratio equal to or greater than 1 m² per gram.

51. The method of any one of claims 33 to 49, wherein the granules have a mean surface area to mass ratio equal to or greater than 5 m² per gram.

52. The method of any one of claims 33 to 49, wherein the granules have a mean surface area to mass ratio equal to or greater than 10 m² per gram.

53. The method of any one of claims 33 to 49, wherein the granules have a mean surface area to mass ratio equal to or greater than 20 m² per gram.

54. The method of any one of claims 33 to 49, wherein the granules have a mean surface area to mass ratio that is in the range of 10 m² per gram to 30 m² per gram.

55. The method of any one of claims 33 to 54, wherein the core of the tablet comprises approximately 80% to approximately 92% by weight of ferric citrate.

56. The method of any one of claims 33 to 54, wherein the core of the tablet comprises approximately 85% to approximately 92% by weight of ferric citrate.

57. The method of any one of claims 33 to 54, wherein the core of the tablet comprises approximately 90% to approximately 92% by weight of ferric citrate.
58. The method of any one of claims 33 to 54, wherein the core of the tablet comprises approximately 80% to approximately 90% by weight of ferric citrate.
59. The method of any one of claims 33 to 58, wherein the binder is pregelatinized starch.
60. The method of any one of claims 33 to 59, wherein the lubricant is calcium stearate.
61. The method of any one of claims 33 to 54, wherein the core of the tablet comprises approximately 80% to approximately 90% by weight of ferric citrate, approximately 8% to approximately 15% by weight of pregelatinized, and approximately 1% to approximately 3% by weight of calcium stearate.
62. The method of any one of claims 33 to 58, wherein the binder comprises one or more of hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), sodium alginate, alginic acid, guar gum, acacia gum, xanthum gum, carbopol, cellulose gum (carboxymethyl cellulose), ethyl cellulose, maltodextrin, PVP/VA, povidone, microcrystalline cellulose, starch (partially or fully pregelatinized starch) and methyl cellulose.
63. The method of any one of claims 33 to 59 or 62, wherein the lubricant is magnesium stearate, calcium stearate, sodium stearyl fumarate, or a combination thereof.
64. The method of any one of claims 33 to 63, wherein the ferric citrate tablet comprises approximately 1000 mg of ferric citrate.
65. A ferric citrate tablet produced by the method of any one of claims 33 to 64.

66. Use of the ferric citrate tablet of claim 65 for the prophylaxis or treatment of hyperphosphatemia in a patient.
67. Use of the ferric citrate tablet of claim 65 for formulating a medicament for the prophylaxis or treatment of hyperphosphatemia in a patient.
68. The ferric citrate tablet of claim 65 for use in the prophylaxis or treatment of hyperphosphatemia in a patient.
69. The ferric citrate tablet of claim 65 for use in formulating a medicament for the prophylaxis or treatment of hyperphosphatemia in a patient.
70. Use of the ferric citrate tablet of claim 65 for formulating a medicament for controlling serum phosphorus levels in an end-stage renal disease patient.
71. Use of the ferric citrate tablet of claim 65 for controlling serum phosphorus levels in an end-stage renal disease patient.
72. The use of claim 70 or 71, wherein the patient is on hemodialysis.
73. The ferric citrate tablet of claim 65 for use in controlling serum phosphorus levels in an end-stage renal patient.
74. The ferric citrate tablet of claim 65 for use in formulating a medicament for controlling serum phosphorus levels in an end-stage renal disease patient.
75. The ferric citrate tablet of claim 73 or 74, wherein the patient is on hemodialysis.
76. The use of any one of claims 23 to 24, 27 to 29, 66 to 67 or 70 to 72, wherein the patient is human.

77. The ferric citrate tablet of any one of claims 25 to 26, 30 to 32, 68 to 69 or 73 to 75, wherein the patient is human.

1/9




FIG. 1

2/9




FIG. 2

3/9




FIG. 3

4/9




FIG. 4

5/9




FIG. 5

6/9




FIG. 6

7/9




FIG. 7

8/9




FIG. 8




FIG. 9

HARDNESS VS. COMPRESSION FORCE




FIG.1